Rexahn Pharmaceuticals Inc.

BioWorld Insight: CNS Discovery, Glass Half Full or Half Empty?

Anette Breindl, Science Editor for BioWorld Today wrote an interesting article that in BioWorld Insight on the current state of state of CNS discovery. Despite some Big Pharma backing away from CNS, the field is percolating with fresh drug candidates and opportunities led [...]

Dr. Chang Ahn, CEO of Rexahn, discusses the promising effects of clavulanic acid – the active ingredient in Rexahn’s Phase2 drugs Serdaxin and Zoraxel.

Rexahn CEO, Dr. Chang Ahn, discusses Serdaxin as a potential treatment for Parkinson’s. Read the article in page 2 of the report here.

Rexahn announced that it has engaged renowned investment banker Frederick Frank, as an independent consultant, to advise on a range of corporate activities.

Rexahn to Initiate ZoraxelTM Phase II Trial for Erectile Dysfunction

In this video Dr. Chang Ahn discusses Rexahn and Phase IIa results of Serdaxin in MDD.

Rockville, MD, April 15, 2010 – Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN) today announced that it will present pre-clinical data on its anticancer compound RX-8243 at the American Association for Cancer Research (AACR) 101st Annual Meeting, held in Washington, D.C., April 17-21, 2010, at the Walter E. Washington Convention Center.

Rexahn Pharmaceuticals hopes this will be its big year. With three candidates in various stages of Phase II development and cash projected to last through the first quarter of 2011, Rexahn feels it should be able to land at least one major deal to either co-develop or out-license one its lead programs…

When it comes down to it, my “biotech geek squad” and I have been digging and researching this company since we stumbled upon it weeks ago and frankly, we felt a need to somewhat rush this report out for our readers.